Esperion Therapeutics Reports Sooner Than Expected Positive Data From Nexletol Trial

• Esperion Therapeutics Inc's (NASDAQ: ESPR) CLEAR Outcomes trial met its primary endpoint, demonstrating statistically significant risk reduction in MACE-4 in patients treated with 180 mg/day NEXLETOL (bempedoic acid) compared to placebo.

• The data demonstrate statistically significant and clinically meaningful results.

• The study included over 14,000 patients at over 1,200 sites in 32 countries.

• Bempedoic acid becomes the first ATP citrate lyase inhibitor and oral non-statin to meet the major adverse cardiovascular events (MACE-4) primary endpoint.

• NEXLETOL is indicated as an adjunct to diet and maximally tolerated statin therapy for heterozygous familial hypercholesterolemia or established atherosclerotic cardiovascular disease who require additional lowering of LDL-C.

• The company reported CLEAR Outcomes trial data sooner than expected in January 2023.

• In Q3, NEXLETOL generated sales of $14 million, up 28% Y/Y.

• The company looks forward to sharing this data with the medical community and submitting it to appropriate regulatory authorities as quickly as possible in 2023.

• Price Action: ESPR shares are up 2.55% at $7.25 on the last check Wednesday.

See more from Benzinga

• Avrobio Touts New Positive Data From Gaucher Disease Gene Therapy

• Replimune Shares Surge After Early Data From Pretreated Melanoma Patients

• Trump's Billionaire Neighbor Warned The Economy Was In An 'Omnibubble,' He Was Right

Don't miss real-time alerts on your stocks - join Benzinga Pro for free! Try the tool that will help you invest smarter, faster, and better.

© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.